Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in cipla

Cipla Unit Gets Notice From US Firm For Termination Of Acquisition Deal

Cipla had announced that InvaGen Pharmaceuticals Inc has entered into definitive agreements to acquire US-based speciality business firm Avenue Therapeutics for up to USD 215 million

Read More

Eli Lilly To Transfer Rights Of Two Diabetes Products To Cipla

The Gurgaon-based firm, which is a wholly-owned subsidiary of US-based Eli Lilly and Company, has inked a pact with Cipla in this regard.

Read More

Cipla, Kemwell Form JV For Developing, Commercialising Biosimilars

'This development reinforces our strength as leaders in respiratory therapy and is in line with our aspiration of global lung leadership,' Cipla Managing Director and Global Chief Executive Officer (CEO) Umang Vohra said.

Read More

Cipla Gets USFDA Nod For Inhalation Product

Brovana is used in maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Read More

Avenue Therapeutics Gets Second Complete Response Letter From USFDA For Intravenous Tramadol

The CRL stated that the delayed and unpredictable onset of analgesia with intravenous tramadol does not support its benefit as a monotherapy to treat patients in acute pain

Read More

Seeking Clarity, Guidance From Govt For Vaccine Import: Cipla

Shares of Cipla closed at Rs 946.40 per scrip on BSE, down 0.29 per cent from its previous close.

Read More

Cipla Launches RT-PCR Test Kit 'Viragen' In India Partnership With Ubio Biotech

Cipla will launch ViraGen test kit in the country in partnership with Ubio Biotechnology Systems

Read More

Cipla Q4 Profit Up 73 % At Rs 412 Cr

Total revenue from operations rose to Rs 4,606 crore as compared with Rs 4,376 crore in the same period of 2019-20, Cipla said in a regulatory filing.

Read More

Scaled Up Remdesivir Production Two-Fold: Cipla

The Centre on Tuesday said doctors should ensure 'rational and judicious' use of remdesivir, underlining it is to be given only to serious COVID-19 patients in hospitals and is not to be used in home settings

Read More

Sensex closes above 50K mark led by pharma, financials

Sensex closes above 50K mark led by pharma, financials

Read More

Equity gauges in the green, pharma stocks in focus

Equity gauges in the green, pharma stocks in focus

Read More

Equity indices flat as banking, financial scrips shed gains

Equity indices flat as banking, financial scrips shed gains

Read More

Equities Trade In Thin Range, Sensex Tests 47K Mark

The BSE S&P Sensex opened at 47,026 but levelled to 46,961 at the close, up 70 points or 0.15 per cent from yesterday's close. The Nifty 50 was up by 20 points or 0.14 per cent at 13,761.

Read More

Leading With People-First Approach

Cipla reported 17 lost time injuries and has an injury frequency of 0.38 for its permanent employees, which are also lower than its peers in the sector.

Read More

Equity indices in the green, metal stocks shine

Equity indices in the green, metal stocks shine

Read More